Mammen Chandy

Mammen Chandy

Auto-generated profile, based on publicly available information

Mammen Chandy

Dept. of Haematology, Christian Medical College, Vellore, India

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2020 in Indian Journal of Hematology and Blood Transfusion
Verified
Journal Article
Closed access
PDF file
ANArijit Nag
Arijit Nag
VRVivek S. Radhakrishnan
Vivek S. Radhakrishnan
JKJeevan Kumar
Jeevan Kumar
SBSaurabh Bhave
Saurabh Bhave
DMDeepak Kumar Mishra
Deepak Kumar Mishra
MCMammen Chandy
Mammen Chandy

8 July 2015 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Open access
PDF file
RBRamkrishna Bhalchandra
Ramkrishna Bhalchandra
SBSanjay Bhattacharya
Sanjay Bhattacharya
JSJeeva Ratnam Soundaranayagam
Jeeva Ratnam Soundaranayagam
SGSubrata Garai
Subrata Garai
MCMammen Chandy
Mammen Chandy

1 January 2022 in Indian Journal of Medical Microbiology
Verified
Journal Article
Closed access
SSSunanda Sahoo
Sunanda Sahoo
SMSudipto Mandal
Sudipto Mandal
PDParijat Das
Parijat Das
SBSanjay Bhattacharya
Sanjay Bhattacharya
MCMammen Chandy
Mammen Chandy

12 March 2021 in Indian Journal of Hematology and Blood Transfusion
Verified
Journal Article
Closed access
PDF file
DBDebapriya Basu
Debapriya Basu
SBSabita Basu
Sabita Basu
VRVivek S. Radhakrishnan
Vivek S. Radhakrishnan
SBSanjay Bhattacharya
Sanjay Bhattacharya
SCSubhosmito Chakraborty
Subhosmito Chakraborty
MCMammen Chandy
Mammen Chandy

1 June 2023 in Transplant Infectious Disease
Verified
Journal Article
Closed access
SGShouriyo Ghosh
Shouriyo Ghosh
SBSanjay Bhattacharya
Sanjay Bhattacharya
GGGaurav Goel
Gaurav Goel
RDRasika Avinash Deshmukh
Rasika Avinash Deshmukh
RJRizwan Javed
Rizwan Javed
MCMammen Chandy
Mammen Chandy

1 April 2021 in Indian Journal of Medical and Paediatric Oncology
Verified
Journal Article
Open access
PDF file
VRVivek S. Radhakrishnan
Vivek S. Radhakrishnan
KMKetan Modak
Ketan Modak
SBSaurabh J. Bhave
Saurabh J. Bhave
JKJeevan Kumar
Jeevan Kumar
MRMita Roychowdhury
Mita Roychowdhury
MCMammen Chandy
Mammen Chandy
Relapsed and refractory (RR) acute lymphoblastic leukemia (ALL) poses unique and difficult challenges to a practicing clinician in India where access to novel immunotherapies is limited. Between 2017 and 2020, eight patients with B-cell ALL at our center received inotuzumab ozogamicin (IO) monotherapy on compassionate access, as salvage therapy after at least two lines of conventional therapy failure, and most often as outpatient infusion. Eight patients (21–60 years, three females) received IO. Three patients had morphologic relapse and five patients reported persistent measurable residual disease (MRD). The best response on IO therapy achieved was negative MRD in six of seven patients and complete response (CR) with persistent MRD in one. One patient died (intracranial hemorrhage) before completion of first cycle. All responding patients were transplant eligible and four patients (57%) underwent allogeneic hematopoietic cell transplantation (Allo-HCT). Median follow-up of this cohort is 9 months (4–29.6 months), four patients (57%) are alive as stable with negative MRD. No significant infusion reactions occurred during therapy. Three patients developed grades III and IV neutropenia, two patients showed grade III transaminitis, and two patients developed post-HCT severe sinusoidal obstruction syndrome (SOS). IO is a feasible outpatient based salvage therapy to improve the remission status in RR B-cell ALL.